Mehr »
Freitag, 23.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Relay Medical Insider kaufen jetzt zu!



24 h / 7 T
7 Tage



24 h / 7 T
7 Tage











Erweiterte Suche
217 Leser
Artikel bewerten:

Cannabix Technologies Releases Images of Beta 2.0 Cannabix Marijuana Breathalyzer / Cannabix and University of Florida make significant strides in developing benchtop FAIMS technology into a portable Cannabix Marijuana Breathalyzer

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 11/11/16 -- Editors Note: There are two photos associated with this press release.

Cannabix Technologies Inc. (CSE: BLO)(CSE: BLO.CN)(CNSX: BLO)(OTC PINK: BLOZF) (the "Company or Cannabix"), developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to release images of its Beta 2.0 Cannabix Marijuana Breathalyzer. New images of the device can be viewed at

Cannabix has been using a methodical iterative product development process to develop its marijuana breathalyzer. Using this method, the product is developed in several prototype stages with each stage used to advance the product to subsequent stages. Cannabix has systematically moved the development of the Cannabix Marijuana Breathalyzer from a concept stage to its Beta 2.0 prototype. The following is a chronology of development highlights:

--  August 2015 - Cannabix entered into a research and option agreement to
    develop a cutting-edge breath detection sensor based upon high-field ion
    mobility coupled with mass spectrometry in collaboration with the Yost
    Research Group at the University of Florida. The Yost Research Group, a
    world leader and pioneer in the development of high-field asymmetric
    waveform ion mobility spectrometry, known as FAIMS. Cannabix and The
    Yost Research Group began working together to identify
    Tetrahydrocannabinol (THC - the psychoactive component of marijuana that
    causes intoxication) in ultra low ranges using highly a sensitive FAIMS-
    mass spectrometer benchtop system. The Company entered into a definitive
    license agreement with the University of Florida for US Patent 8,237,118
    in the summer of 2016 which provided the Company exclusive worldwide
    rights in the area of breath analysis of controlled substances.

--  June 2016 - Cannabix Scientists and Dr. Rick Yost at the University of
    Florida developed a standalone desktop-sized "Beta 1.0" FAIMS based
    device with a proprietary configurable high voltage power supply which
    operated with conventional power sources. The FAIMS cell employed in
    "Beta 1.0" device was 4X smaller than the prior benchtop version and had
    achieved a 10X reduction in power supply size, which allowed for a
    drastically smaller footprint. The Beta 1.0 included a power supply that
    was readily configurable for ongoing testing and was designed to
    integrate with a non-radioactive ionization source.

--  October 19, 2016 - Cannabix developed its "Beta 2.0" Cannabix Marijuana
    Breathalyzer with major advances in the design and size of the device,
    including: greater sensitivity, improved performance by the square
    waveform generator and a much smaller size for all components. The Beta
    2.0 design included features to allow for the addition of a rechargeable
    battery and touch screen and the device is approximately 10 times
    smaller than the Beta 1.0 device. Preliminary lab tests of the FAIMS
    device coupled with quadrupole ion trap mass spectrometry have shown
    lower levels of detection for THC standards than were achieved in past

--  November 11, 2016 - Cannabix provides the first images of the Cannabix
    Marijuana Breathalyzer "Beta 2.0" device. Images show components housed
    in a durable compact black box which has been reduced in size to be a
    portable device. The device encompasses the latest chip technology to
    improve speed performance, FAIMS detection technology, conventional
    battery and updated square wave generator. Cannabix believes that the
    Beta 2.0 Cannabix Marijuana Breathalyzer which utilizes FAIMS detection
    technology is the most sensitive and scientifically proven method of
    detection of volatile compounds found at trace levels in exhaled breath.

The Beta 2.0 prototype encompasses a robust detection system and components platform that will be used in an eventual finalized product for manufacturing. The Beta 2.0 prototype has provided excellent sensitivity in lab testing and will be utilized to conduct scientific studies with live marijuana users (smokers and edible consumers) to test the device for its accuracy and sensitivity using a controlled scientific testing protocol. The results of the scientific test will be used to prepare submissions for approval of the Cannabix Marijuana Breathalyzer as a court-approved device by the Minister of Justice in Canada and the National Highway Traffic Safety Administration (NHTSA) in the United States. In addition, law enforcement officials and regulators for the Minister of Justice and the NHTSA will be consulted regarding additional features, roadside protocol, ease of use, and to define a final housing design for a finished product.

The scientific testing protocol will be designed by the Cannabix's Dr. Raj Attariwala, with input from the Company's team of exceptional Scientific Advisors. Additional input on the trial testing will be sought from consultants who are familiar with obtaining regulatory approvals for court certified device from the Minister of Justice in Canada and the NHTSA in the USA.

Professor Richard Yost, Head of Analytical Chemistry at the University of Florida and Scientific Advisor on the FAIMS Cannabix Marijuana Breathalyzer states:

"When Cannabix first approached our lab with the goal of building a device that could detect trace amounts of THC through exhaled breath, we were excited to face the challenge. We have been able to use our expertise and patent in FAIMS technology and build a device that achieves the required sensitivity and specificity but also will be a handheld portable device, similar to alcohol breathalyzers. We are extremely pleased and proud to be working on the design of a portable Cannabix Marijuana Breathalyzer that will be used by Law Enforcement to collect evidence of impaired driving and ensure safety on our roads as marijuana use becomes accepted in society and its use continues to grow."

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC - the psychoactive component of marijuana that causes intoxication - using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

Rav Mlait, CEO, Cannabix Technologies Inc.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

To view the photos associated with this release, please visit the following links:

Cannabix Technologies Inc.
(604) 551-7831

Kostenloser Wertpapierhandel auf
© 2016 Marketwired
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.